Provided by Tiger Trade Technology Pte. Ltd.

Alterity Therapeutics Limited

4.52
-0.0300-0.66%
Post-market: 4.520.00000.00%16:10 EDT
Volume:7K
Turnover:33.32K
Market Cap:81.93M
PE:-4.90
High:4.61
Open:4.52
Low:4.50
Close:4.55
52wk High:5.89
52wk Low:2.66
Shares:18.13M
Float Shares:14.48M
Volume Ratio:0.31
T/O Rate:0.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9231
EPS(LYR):-0.9231
ROE:-54.98%
ROA:-31.75%
PB:2.67
PE(LYR):-4.90

Loading ...

Craig-Hallum bullish on Alterity Therapeutics, initiates with a Buy

TIPRANKS
·
Aug 11

Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference

GlobeNewswire
·
Aug 06

Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update

GlobeNewswire
·
Jul 30

Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026

GlobeNewswire
·
Jul 21

Alterity Therapeutics initiated with a Buy at JonesResearch

TIPRANKS
·
Jun 30

Alterity Therapeutics assumed with a Buy at Ladenburg

TIPRANKS
·
Jun 16

Top Premarket Decliners

MT Newswires Live
·
Jun 11

Alterity Therapeutics achieves alignment with FDA on program for ATH434 in MSA

TIPRANKS
·
Jun 09

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

GlobeNewswire
·
Jun 09

Alterity Therapeutics publishes quantitative susceptibility mapping MRI data

TIPRANKS
·
May 11

Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026

GlobeNewswire
·
May 07

Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

GlobeNewswire
·
Apr 30

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

GlobeNewswire
·
Apr 22

Alterity Therapeutics appoints Ann Cunningham to board as independent director

Reuters
·
Apr 17

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy

GlobeNewswire
·
Apr 15

Alterity Therapeutics appoints Daniel Claasen as chief medical advisor

TIPRANKS
·
Mar 04

Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

GlobeNewswire
·
Mar 04

Alterity Therapeutics recognizes MSA Awareness Month

TIPRANKS
·
Mar 02

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

GlobeNewswire
·
Mar 02